U.S Govenment Announces $450M Deal With Regeneron Pharmaceuticals

U.S Govenment Announces $450M Deal With Regeneron Pharmaceuticals

The combined forces of the Biomedical Advanced Research and Development Authority (BARDA), the U.S. Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense have just approved a $450M deal with Regeneron Pharmaceuticals, Inc. This $450 million contract is for Regeneron to manufacture and supply REGN-COV2. REGN-COV2 is Regeneron's investigational double-antibody cocktail for COVID-19 treatment and prevention. Regeneron is currently in Phase 2/3 of clinical trials for the...

Lawmakers Urge HHS To Increase Clinical Lab Funding

Lawmakers Urge HHS To Increase Clinical Lab Funding

Due to the extensive work that clinical laboratories have been doing towards the COVID-19 relief, lawmakers urge HHS To increase clinical lab funding. They're urging Secretary Alex Azar of Health and Human Services to direct funds from the Public Health and Social Services Emergency Fund, PHSSEF, to financially support these labs.  These labs are doing extensive research on the COVID-19 testing forefront. It is vital for these labs to have the finances and support needed to accurately and efficient test...

CA and NY Voting on Additional COVID 19 Lab Funding

In recent news, Tom Reed (NY-23) and Scott Peters (CA-52) sent a request asking HHS to allocate a portion of the Public Health and Social Services Emergency Fund, PHSSEF, toward the clinical labs that have been testing extensively for COVID-19. There has since been a need in CA and NY for additional COVID 19 lab funding. Reed describes that these clinical labs have stepped up during this pandemic, including significant investments done to increase the capacity of these tests. He...

COVID-19 Funds To Go Directly to Labs

US Congress Wants COVID-19 Funds To Go Directly to Labs

There are efforts being made by 30 US Congress members who want COVID-19 funds to go directly to labs focusing on COVID-19 testing. Already there is an act titled, Paycheck Protection Program and Health Care Enhancement Act, which invests $25 billion to further research aspects of COVID-19 testing. While this money goes to states in order to enhance their testing abilities, there have been zero federal funds reserved for the labs that have stepped up their facilities including, buying PPE...

Flood of Different COVID-19 Serology Tests Bad News for Clinical Labs

Flood of Different COVID-19 Serology Tests Bad News for Clinical Labs

Is the flood of different COVID-19 serology tests bad news for clinical labs? Yes and no. Clinical laboratory managers and pathologists are well aware of the big undertaking it can be to select, validate, and implement a new COVID-19 serology test. The tests are brand new and abundant, and accuracy is an issue.  But, a pro of these serology tests is the abundance of testing means an opportunity for financial gains, especially for labs with shelter-in-place orders since early March. ...

Pandemic Tips from Healthcare Professionals

COVID-19 has caused countless issues for labs, hospitals, and healthcare providers. Supply shortages, testing delays, and lack of safety equipment have been a few of the daily issues. This blog will list some pandemic tips from healthcare professionals. Becker's Hospital Review hosted a podcast offering advice from industry leaders on how they're coping. Here are some of the highlights: Lab supply chain Bryan Vaughn, senior vice president of hospital and health services at LabCorp: "At LabCorp, choice of [testing] platform to bring...

Lab Offshore Billing Could be Costly in the Long Run

Attempting to cut costs of clinical laboratory test billing, a number of labs and pathology groups have moved billing and collections to overseas companies. These companies are charging nearly half of what American billing companies charge; yet, along with the cheaper rates the groups are experiencing a sharp drop in revenue - up to 30-40% or more.  This decline in revenue is due to the fact that most of these offshore companies may not resubmit rejected claims or go after...

$150M Dallas Laboratory Fraud Case

Former co-owner of Next Health LLC, Andrew Hillman which included a network of drug and genetic-testing labs based in Dallas, plead guilty on charges of violating deferrals anti-kickback laws. He plead guilty to this Dallas laboratory fraud case in 2018 and has been sentenced to 66 months in prison and required to pay $3 million in restitution for his role in fraud, doctor kickbacks, bribery, and money laundering. Owners Andrew Hillman and Semyon Narosov pleaded guilty to accounts of medical...

Clinical Lab and Anatomic Pathology Leaders Face 2020 Challenges

The ongoing and reformative changes in the American healthcare system are triggering tough challenges for leaders of the nation's clinical laboratories and anatomic pathology groups. There are two basic pillars to the nation's healthcare reform, one is the integration of medical care to keep people out of hospitals - which are the most expensive sites of care - and to further proactively manage current patients to keep them healthy.  The second is a change in reimbursement structuring, policymakers in 2020...

Assessing the Clinical Utility of Patient Requested Lab Tests

Due to skilled and sometimes aggressive marketing that enthusiastically directs patients and labs towards new, proprietary tests, laboratorians must be diligent about assessing the evidence-based clinical utility of the tests.  A large part of the difficulty in this task lies in the fact that often patient requested testing is a response to clinical conditions that involve profound patient suffering. Naturally, the patient wanting to understand more about their condition in the face of their own suffering is understandable. This increases...